Video

VIDEO: Time to skip chemo for luminal A tumors?


 

AT SABCS 2015

References

SAN ANTONIO – Premenopausal women with luminal A tumors did not derive benefit from adjuvant cyclophosphamide-based chemotherapy.

In an interview, Dr. Torsten Nielsen, professor of pathology at the University of British Columbia in Vancouver, discusses the prospective-retrospective study and whether its findings will prompt patients with these tumors and their physicians to skip chemotherapy.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

AHA: Older breast cancer patients more likely to die of heart disease than malignancy
MDedge Hematology and Oncology
What’s anticipated at SABCS 2015?
MDedge Hematology and Oncology
Die not yet cast for lymphazurin and methylene blue dye
MDedge Hematology and Oncology
High risk for getting breast cancer linked with low risk of metastasis
MDedge Hematology and Oncology
VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer
MDedge Hematology and Oncology
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancer
MDedge Hematology and Oncology
VIDEO: Adjuvant capecitabine has role for residual disease after neoadjuvant therapy
MDedge Hematology and Oncology
VIDEO: Triple-negative breast cancer outcomes boosted by adding carboplatin to neoadjuvant chemo
MDedge Hematology and Oncology
VIDEO: Mastectomy plus reconstruction has highest complication rates of all early BC treatment options
MDedge Hematology and Oncology
VIDEO: APOBEC3B enzyme may limit tamoxifen efficacy
MDedge Hematology and Oncology